A fludarabine-based conditioning regimen for severe aplastic anemia

• Published in: Bone marrow transplantation (Basingstoke) Vol. 27; no. 2; pp. 125 - 128
• Main Authors: CHAN, K. W, LI, C. K, WORTH, L. L, CHIK, K. W, JEHA, S, SHING, M. K, YUEN, P. M
• Format: Journal Article
• Language: English
• Published: Basingstoke Nature Publishing Group 2001
• Subjects: Anemia; Anemia, Aplastic - therapy; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antigens; Aplastic anemia; Biological and medical sciences; Bone marrow; Bone marrow transplantation; Bone marrow, stem cells transplantation. Graft versus host reaction; Child; Child, Preschool; Chimerism; Combined Modality Therapy; Complications; Conditioning; Cyclophosphamide; Female; Fludarabine; Globulins; Graft rejection; Graft Survival; Hematopoietic Stem Cell Transplantation; Histocompatibility antigen HLA; Humans; Immunosuppressive Agents - administration & dosage; Infant; Irradiation; Medical sciences; Radiation; Stem cell transplantation; Thymocytes; Toxicity; Transfusions. Complications. Transfusion reactions. Cell and gene therapy; Transplantation; Transplantation Chimera; Transplantation, Homologous; Transplants & implants; Vidarabine - administration & dosage; Vidarabine - analogs & derivatives; Human; Purine nucleotide; Drug combination; Aplastic anemia; Homograft; Hemopathy; Chemotherapy; Cyclophosphamide; Oxazaphosphinane derivatives; Fludarabine; Treatment; Nitrogen mustard; Bone marrow; Graft; Immunosuppressive agent; Pretreatment; Child; Antithymocyte globulin
• ISSN: 0268-3369; 1476-5365
• DOI: 10.1038/sj.bmt.1702768

Graft rejection is a common problem after alternative donor transplantation for patients with refractory severe aplastic anemia (SAA). Intensification of the conditioning regimen, with the inclusion of irradiation, has often been advocated to combat this problem. With this approach engraftment rate improved, but the incidence of transplant-related complications is also increased, resulting in little change in the overall outcome. We investigated the use of the combination of fludarabine, cyclophosphamide and anti-thymocyte globulin as the conditioning regimen in five multiply-transfused SAA patients. Three patients received an HLA one-antigen disparate related donor transplant, while two patients were given marrow from matched, unrelated donors. The regimen was well tolerated, with only grade I toxicity encountered. With a median follow-up of 9 months, all patients are alive with complete donor chimerism. We conclude that fludarabine may be used in place of irradiation to augment the conditioning regimen of cyclophosphamide and anti-thymocyte globulin for alternative donor transplantation in children with SAA.